Surgical Risk in the Portal Hypertensive Patient

Product not yet rated

Recorded On: 03/07/2018

The webinar will focus on the best practices and the underlying evidence in terms of surgical management of the portal hypertensive patient. A practical approach will be outlined whereby patient risk, assessment, and management will be discussed. This is an essential and daily part  of practice for hepatologists and this  webinar will update and educate as to current management.

Brett E. Fortune (Moderator)

Dr. Brett E. Fortune, MD, MSc, is a Transplant Hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation. His research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.

Theo Heller (Moderator)

Dr. Heller is a senior clinical investigator at the National Institutes of Health where he heads the Translational Hepatology Section. His research focuses on liver disease progression with a particular focus on non-cirrhotic portal hypertension as a model for all patients with portal hypertension. He is focused on enhancing the clinical care of patients with portal hypertension while elucidating mechanisms that underlie the development of portal hypertension due to any etiology. His research encompasses translational and clinical techniques with the ultimate aim of ensuring superb outcomes for patients with liver disease.

 

Lawrence S. Friedman

Dr. Lawrence S. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins School of Medicine combined BA/MD program. He did his residency training at Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital. He was on the faculty of Jefferson Medical College, where he served as Vice Chairman of the Department of Medicine and a member of the Gastrointestinal Unit at Massachusetts General Hospital. He is Professor of Medicine at Harvard Medical School and Tufts University School of Medicine. Since July 1, 2003, he has been Chair of the Department of Medicine at Newton-Wellesley Hospital and Assistant Chief of Medicine at Massachusetts General Hospital.

Manuel I. Rodriguez-Davalos

Dr. Manuel Rodriguez-Davalos is currently the surgical director of pediatric liver transplantation at Primary Children’s Hospital in Salt Lake City, Utah, and the medical director of the living donor liver transplantation program at Intermountain Medical Center. He was an Associate Professor of Surgery and Pediatrics at the Yale School of Medicine, where he was also the Director of Pediatric Transplantation at the Yale New Haven Transplantation since 2012. He was the liver review board primary representative for CTYN and served as Region 1 representative in the OPTN/UNOS Pediatric Transplantation Committee. He has been involved in research of ischemia reperfusion injury and the development of novel means for perfusion and preservation techniques to improve graft quality, expand the donor pool. His projects during the past 5 years in translational research involve the use of partial grafts and extended criteria for donation in liver transplantation, preservation techniques for decreasing ischemia-reperfusion injury in intestinal and liver grafts. He is collaborating with the Yale School of Engineering on the design and use of new perfusion devices for organ preservation and research.

Components visible upon registration.